UniQure ‘Exceeds Expectations’ in Much-Anticipated 3-Year Huntington’s Readout

uniQure's gene therapy, AMT-130, for Huntington's disease, demonstrated a statistically significant 75% slowing of disease progression in three-year Phase I/II trial data, exceeding analyst expectations and driving uniQure shares up 156% in pre-market trading. This positive outcome, which also met a key secondary endpoint, positions the company to submit a Biologics License Application (BLA) in Q1 2026 for what could become the first genetic treatment for the neurodegenerative condition, marking a significant advancement in a therapeutic area previously characterized by clinical setbacks.

Analysis

UniQure's gene therapy, AMT-130, has delivered exceptionally strong three-year data from its Phase I/II trial in Huntington's disease, significantly de-risking its clinical profile. The therapy demonstrated a 75% slowing of disease progression on the primary cUHDRS endpoint compared to an external control, a result that was statistically significant and "clearly exceeded" Stifel analyst expectations of approximately 60%. This positive outcome, which propelled the company's stock up 156% in pre-market trading, was further supported by meeting a key secondary endpoint on Total Functional Capacity (TFC) and showing a reduction in neurofilament light (NfL) levels, a key biomarker for neurodegeneration. Critically, the three-year data shows strong consistency with the 80% slowing observed at the two-year mark, a key requirement set by management to support a submission for conditional approval. With a manageable safety profile and alignment with the FDA on an accelerated pathway, uniQure plans a Biologics License Application (BLA) submission in the first quarter of 2026, positioning AMT-130 to potentially become the first-ever genetic treatment in a therapeutic area marked by previous high-profile failures from competitors.

Key Decisions for Investors

• The robust and consistent efficacy data significantly de-risks the clinical outlook for AMT-130, warranting a bullish re-evaluation of uniQure's long-term value, though investors should be mindful that the initial 156% stock surge has likely priced in much of the immediate upside.
• The key catalyst has now shifted from clinical data to regulatory execution, so investors should closely monitor uniQure's progress toward its Q1 2026 BLA submission and any FDA feedback regarding the accelerated approval pathway and use of an external control group.
• Given the substantial run-up in share price, it is prudent to consider the potential for a capital raise to fund commercialization efforts, as this creates an opportune window for the company to secure financing ahead of its planned 2026 launch.
• Despite uniQure's clear lead, the competitive landscape should not be ignored; watch for progress from Wave Life Sciences and PTC Therapeutics, as developments in their programs could impact the future market share and pricing power of AMT-130.